Sal Daher, CFA

Chinese drug discovery biotech HitGen is teaming up with U.K.-based Cambridge Molecular to better seek out new drugs.

Pfizer’s oral COVID-19 antiviral has cut the risk of hospitalization or death by 85% in a late-phase trial, prompting the Big Pharma to stop the study and race to seek emergency use authorization from…

ReWalk Robotics is picking up the pace in its trek down the FDA’s review pathway.

Moderna has suffered an early blow to its move beyond prophylactic vaccines, revealing it won’t take the lead candidate in one of its core modalities into phase 2. The mRNA player removed the drug…

Northwestern University researchers found that a gene therapy targeting the region of the brain that houses dopamine-releasing neurons could boost the effectiveness of the widely used Parkinson’s drug…

For the third quarter in a row, iRhythm Technologies continued its streak of increasing revenues, amid a host of challenges ranging from staffing shortages to lower-than-expected Medicare…

Mirati Therapeutics parted ways with its chief medical and operating officers as the biotech gets nearer to asking the FDA to approve its first drug. Moderna’s former chief medical officer chooses VC…

Startups, BioPharma Researchers have known for decades that viruses can beat back cancer. But it’s been hard to design a virus that does the trick. A new wave of startups is optimistic they have found the keys. https://medcitynews.com/author/jberg

Veronica Gambillara Fonck, Ph.D., has been one member of a group of scientists that have followed each other across a dizzying landscape of spin offs and new ventures in vaccines R&D. Now the team has…

Researchers at the Washington University School of Medicine discovered a long noncoding RNA that regulates the androgen receptor in prostate cancer. Dialing up its expression in mouse models of the…